These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 15826746

  • 1. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
    Magno C, Anastasi G, Morabito N, Gaudio A, Maisano D, Franchina F, Galì A, Frisina N, Melloni D.
    Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
    [Abstract] [Full Text] [Related]

  • 2. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
    Morabito N, Gaudio A, Lasco A, Catalano A, Atteritano M, Trifiletti A, Anastasi G, Melloni D, Frisina N.
    J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
    [Abstract] [Full Text] [Related]

  • 3. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Nov; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
    Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, Fleshner N, Krahn MD, Naglie G, Tannock IF, Tomlinson G, Warde P, Duff Canning S, Cheung AM.
    Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [Abstract] [Full Text] [Related]

  • 10. Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy.
    Ziaran S, Goncalves FM, Breza JS.
    Endocr Regul; 2011 Oct; 45(4):199-204. PubMed ID: 22073949
    [Abstract] [Full Text] [Related]

  • 11. Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.
    Wu C, Chen W, Huang X, Lin R, Wu J, Zhang X.
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1243-e1250. PubMed ID: 30146230
    [Abstract] [Full Text] [Related]

  • 12. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S, Lloret M, Naranjo A, Déniz F, Chesa N, Domínguez C, Lara PC.
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [Abstract] [Full Text] [Related]

  • 13. [Maximal androgen blockade little influences bone mineral density in prostate cancer patients].
    Sun GF, Yang B, Zhu H, Li NC, Na YQ.
    Zhonghua Nan Ke Xue; 2012 Nov; 18(11):978-81. PubMed ID: 23214245
    [Abstract] [Full Text] [Related]

  • 14. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
    Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T.
    Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
    [Abstract] [Full Text] [Related]

  • 15. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
    Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ.
    J Bone Miner Res; 2004 Aug; 19(8):1221-30. PubMed ID: 15231008
    [Abstract] [Full Text] [Related]

  • 16. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
    Smith MR, Fallon MA, Goode MJ.
    Urology; 2003 Jan; 61(1):127-31. PubMed ID: 12559282
    [Abstract] [Full Text] [Related]

  • 17. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ, Srinivas S, Perkash I, Terris MK.
    Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
    [Abstract] [Full Text] [Related]

  • 18. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR.
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [Abstract] [Full Text] [Related]

  • 19. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
    Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P, Duff-Canning S, Krahn M, Naglie G, Tannock I, Tomlinson G, Alibhai SM.
    BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
    [Abstract] [Full Text] [Related]

  • 20. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.